Download App

Log in to access Online Inquiry
Company Overview More
Shanghai Fuhong Hanlin Biotechnology Co., Ltd. is a Chinese company mainly engaged in the research, development, production and sales of monoclonal antibody products. The company's main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) bioanalogue HLX02, trimethoprim (adamumab) bioanalogue HLX03 and Avetine (bevacizumab) bioanalogue HLX04, as well as candidate biological innovation drugs. It includes HLX06 (a new type of VEGFR2 inhibitor), HLX07 (a kind of EGFR inhibitor), HLX10 (a new type of PD-1 inhibitor), HLX20 (a new type of PD-L1 inhibitor) and HLX22 (a new type of HER2 inhibitor). The company also provides related technical services. The company mainly operates in China and the United States.
CEO: Wenjie Zhang
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

02696 HENLIUS-B
16.920+1.040+6.55%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Assets
Current assets
Inventory
37.64% 420.11M 110.14% 346.74M 135.02% 305.22M 144.84% 165M
Accounts receivable
50.72% 295.74M 152.06% 216.41M 557.77% 196.21M 388.51% 85.86M
Advance deposits and other receivables
-23.88% 223.97M -25.58% 197.12M 49.86% 294.25M 68.53% 264.88M
Cash and equivalents
-36.52% 707.33M 7.46% 1.23B -51.57% 1.11B 225.54% 1.15B
Secured deposit
-- -- -- -- -- -- 41.52% 9.35M
Total current assets
-13.76% 1.65B 19.19% 1.99B -28.21% 1.91B 175.66% 1.67B
Non-current assets
Property, plant and equipment
24.77% 1.23B 73.26% 1.12B 96.7% 984.91M 67.77% 647.09M
Intangible assets
23.53% 3.63B 27.72% 3.2B 35.28% 2.94B 48.47% 2.5B
Other illiquid assets
49.57% 223.67M -38.43% 159.34M -27.61% 149.54M -33.02% 258.81M
Special items of non-current assets
-3.11% 438.2M 1.07% 460.35M 26.8% 452.28M 188.8% 455.48M
Total non-current assets
22% 5.53B 27.77% 4.94B 39.83% 4.53B 47.74% 3.86B
Total assets
11.39% 7.17B 25.18% 6.93B 9.14% 6.44B 71.81% 5.54B
Liabilities
Current liabilities
Accounts payable
28.27% 383.47M -15.82% 186.13M 24.48% 298.95M 70.52% 221.11M
Other payables and accrued expenses
97.18% 867.28M 48.18% 406.89M 7.49% 439.85M -4.36% 274.6M
Bank loans and overdrafts
32.16% 1.57B 289.14% 1.63B 327.14% 1.19B 35.89% 418.23M
Investment contract liabilities - current liabilities
-- -- -- 57.18M -- -- -- --
Special items of current liabilities
164.82% 138.3M -- -- 63% 52.23M 245.24% 32.29M
Total current liabilities
49.52% 2.96B 140.71% 2.28B 106.28% 1.98B 28.93% 946.23M
Net current assets
-1788.2% -1.31B -139.36% -285.44M -104.09% -69.51M 668.78% 725.28M
Total assets less current liabilities
-5.53% 4.21B 1.36% 4.65B -9.73% 4.46B 84.46% 4.59B
Non-current liabilities
Long-term bank loan
63.11% 1.05B 265.91% 977.28M 94.82% 645.13M -47.07% 267.08M
Long-term accounts payable
-- 54.43M -- -- -- -- -- --
Deferred income-non-current liabilities
64.12% 155.74M 168.29% 148.01M 162.85% 94.9M 48.26% 55.17M
Investment contract liabilities-non-current liabilities
-- -- -- 656.31M -- -- -- --
Special items of non-current liabilities
25.55% 653.93M -- -- -9.02% 520.87M 40.08% 559.52M
Total non-current liabilities
51.98% 1.92B 102.05% 1.78B 34.17% 1.26B -6.32% 881.78M
Total liabilities
50.48% 4.88B 122.06% 4.06B 70.6% 3.24B 9.13% 1.83B
Total assets less total liabilities
-28.2% 2.3B -22.58% 2.87B -20.04% 3.2B 139.7% 3.71B
Total equity and non-current liabilities
-5.53% 4.21B 1.36% 4.65B -9.73% 4.46B 84.46% 4.59B
Equity
Share capital
0% 543.5M 0% 543.5M 0% 543.5M 14.56% 543.5M
Reserve
-33.97% 1.75B -26.46% 2.33B -23.19% 2.66B 195.05% 3.16B
Legal reserve
-33.97% 1.75B -26.46% 2.33B -23.19% 2.66B 195.05% 3.16B
Shareholders' Equity
-28.2% 2.3B -22.58% 2.87B -20.04% 3.2B 139.7% 3.71B
Total equity
-28.2% 2.3B -22.58% 2.87B -20.04% 3.2B 139.7% 3.71B
Total equity and total liabilities
11.39% 7.17B 25.18% 6.93B 9.14% 6.44B 71.81% 5.54B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
Unqualified Opinion--Unqualified Opinion--
Auditor
Ernst & Young accounting firm--Ernst & Young accounting firm--

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%